Myriad Genetics, Inc. (MYGN)

Myriad Genetics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jun 30, 2020	Jun 30, 2019
Net Income	-234.6	-263.3	-112	-27.2	-199.5	4.6
Depreciation & Amortization	68.9	73.2	64.4	75.6	72	73
Share-Based Compensation	45.2	40.7	38.1	36.3	25.2	33.5
Other Operating Activities	24.2	38.5	-96.8	-66.1	163	-27.4
Operating Cash Flow	-96.3	-110.9	-106.3	18.6	60.7	83.7
Operating Cash Flow Growth	-	-	-	-69.36%	-27.48%	-27.78%
Capital Expenditures	-58.4	-73.3	-45.3	-18	-10.2	-8.6
Acquisitions	0	0	-57.2	379.1	21.3	-278.5
Change in Investments	48.6	105.2	25	-86.7	8.2	0.7
Investing Cash Flow	-9.8	31.9	-77.5	274.4	19.3	-286.4
Share Issuance / Repurchase	123.6	123.6	6.3	91.8	13.3	-26.8
Debt Issued / Paid	38	38.1	-0.7	-227.6	-9.6	223.6
Other Financing Activities	-12.6	-8.8	-13.6	-14.8	-13.7	-14.5
Financing Cash Flow	149	152.9	-8	-150.6	-10	182.3
Exchange Rate Effect	-0.4	0.6	-0.6	-0.6	0.5	2.7
Net Cash Flow	42.5	74.5	-192.4	141.8	70.5	-17.7
Free Cash Flow	-154.7	-184.2	-151.6	0.6	50.5	75.1
Free Cash Flow Growth	-	-	-	-98.81%	-32.76%	-30.14%
Free Cash Flow Margin	-19.98%	-24.46%	-22.35%	0.09%	7.91%	8.82%
Free Cash Flow Per Share	-1.72	-2.23	-1.88	0.01	0.68	1.02

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).